EUVIMEDEUVIMED entdecken
Crossref

PHARMACOLOGICAL TREATMENT OF LYMPHEDEMA: STATE OF THE ART

D.A. Chatzelas, M.I. Kantzas, E.P. Dimakakos

Lymphology · 10.11.2026 · 59 (3)

DOI: 10.2458/lymph.12403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lymphology, online erschienen am 10.11.2026. Verfasst von D.A. Chatzelas und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphedema is a chronic, progressive disorder characterized by impaired lymphatic transport, persistent inflammation, adipose deposition, and tissue fibrosis. Although complete decongestive therapy remains the cornerstone of management, it does not directly modify the biological mechanisms responsible for disease progression. This review summarizes current evidence on the pharmacological treatment of primary and secondary lymphedema. A comprehensive literature search of MEDLINE/PubMed, Scopus, Web of Science, and the Cochrane Library was performed from database inception to June 30, 2026, supplemented by manual reference screening. Experimental studies, clinical trials, observational studies, systematic reviews, and consensus documents evaluating pharmacological, biological, gene-based, and regenerative therapies were included. Conventional agents, including diuretics, benzopyrones, flavonoid-derived veno-active drugs, selenium, and doxycycline, have demonstrated limited or inconsistent clinical benefit. More recently, advances in lymphatic biology have identified promising therapeutic targets, including ketoprofen, selective leukotriene B4 inhibition, topical tacrolimus, interleukin-4/interleukin-13 blockade, trans-forming growth factor-β inhibition, glucagon-like peptide-1 receptor agonists, vascular en-dothelial growth factor-C gene therapy, and cell-based regenerative approaches. Future progress will depend on adequately powered, phenotype-specific clinical trials integrating emerging pharmacological therapies with established conservative and surgical man-agement.

Zitieren

APA

Chatzelas, D., Kantzas, M., & Dimakakos, E. (2026). PHARMACOLOGICAL TREATMENT OF LYMPHEDEMA: STATE OF THE ART. Lymphology, 59(3). https://doi.org/10.2458/lymph.12403

Vancouver

Chatzelas D, Kantzas M, Dimakakos E. PHARMACOLOGICAL TREATMENT OF LYMPHEDEMA: STATE OF THE ART. Lymphology. 2026;59(3). doi:10.2458/lymph.12403

BibTeX
@article{Chatzelas2026,
  author = {Chatzelas, D.A. and Kantzas, M.I. and Dimakakos, E.P.},
  title = {PHARMACOLOGICAL TREATMENT OF LYMPHEDEMA: STATE OF THE ART},
  journal = {Lymphology},
  year = {2026},
  volume = {59},
  number = {3},
  doi = {10.2458/lymph.12403}
}
Kostenlos starten →